Department of Radiotherapy, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuzhou, People's Republic of China.
Fujian Medical University, Fuzhou, People's Republic of China.
Radiat Oncol. 2020 Oct 2;15(1):230. doi: 10.1186/s13014-020-01674-5.
This study aimed to assess the effectiveness and cost-effectiveness of nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).
LA-NPC patients treated between October 2013 and December 2016 were retrospectively reviewed. A well-balanced cohort of patients who received nimotuzumab in addition to standard treatment (n = 50) and patients who did not receive nimotuzumab (n = 100) was selected using propensity score-matching method (1:2 ratio) for the cost-effectiveness analysis.
Compared with concurrent chemoradiotherapy (CCRT) alone, addition of nimotuzumab to CCRT significantly improved the 3-year overall survival (OS) (98.00% vs. 91.00%, P = 0.032). On multivariate analysis, nimotuzumab (hazard ratio = 0.124, 95% confidence interval: 0.017-0.902, P = 0.039) showed prognostic significance for OS. No serious treatment-related adverse events were observed in the nimotuzumab group (P > 0.05). Cost-effectiveness analysis revealed that addition of nimotuzumab increased the average treatment costs by $14,364.63. The additional cost for every one percent increase in OS rate was $ 2,052.09.
Addition of nimotuzumab to CCRT for LA-NPC confers significant survival benefits; however, it is not cost-effective.
本研究旨在评估尼妥珠单抗在局部晚期鼻咽癌（LA-NPC）患者中的疗效和成本效益。
回顾性分析 2013 年 10 月至 2016 年 12 月期间接受治疗的 LA-NPC 患者。采用倾向评分匹配法（1:2 比例），选择接受尼妥珠单抗联合标准治疗（n=50）和未接受尼妥珠单抗治疗的患者（n=100）进行成本效益分析。
与单纯同期放化疗（CCRT）相比，尼妥珠单抗联合 CCRT 可显著提高 3 年总生存率（OS）（98.00% vs. 91.00%，P=0.032）。多因素分析显示，尼妥珠单抗（风险比=0.124，95%置信区间：0.017-0.902，P=0.039）对 OS 具有预后意义。尼妥珠单抗组未观察到严重的治疗相关不良事件（P＞0.05）。成本效益分析显示，尼妥珠单抗的加入增加了平均治疗费用 14364.63 美元。每增加 1%的 OS 率，额外成本为 2052.09 美元。
尼妥珠单抗联合 CCRT 治疗 LA-NPC 可显著提高患者的生存获益，但并不具有成本效益。
